Investigating how Interleukin-27 affects the body's response to Legionella infection
Interleukin-27 in host response to Legionella infection
['FUNDING_R01'] · BOSTON UNIVERSITY MEDICAL CAMPUS · NIH-10871841
This study is looking at how a substance called Interleukin-27 (IL-27) affects the immune system's response to Legionnaires' disease, a serious type of pneumonia, to help us understand how it influences inflammation and immune cell activity in the lungs during infection.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | BOSTON UNIVERSITY MEDICAL CAMPUS (nih funded) |
| Locations | 1 site (BOSTON, UNITED STATES) |
| Trial ID | NIH-10871841 on ClinicalTrials.gov |
What this research studies
This research focuses on understanding the role of Interleukin-27 (IL-27) in the immune response to Legionella infection, which causes Legionnaires' disease, a severe form of pneumonia. The study examines how IL-27 influences inflammation and the behavior of immune cells in the lungs during infection. By analyzing samples from patients and using animal models, researchers aim to uncover the mechanisms by which IL-27 affects the severity of the disease and the body's ability to fight off the infection.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with Legionnaires' disease or those at high risk of developing severe pneumonia due to Legionella infection.
Not a fit: Patients who do not have Legionnaires' disease or are not at risk for this specific infection may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies that enhance the immune response against Legionella, potentially reducing mortality rates associated with Legionnaires' disease.
How similar studies have performed: Previous research has indicated that targeting cytokines like IL-27 can influence immune responses, suggesting that this approach may yield valuable insights into treating Legionnaires' disease.
Where this research is happening
BOSTON, UNITED STATES
- BOSTON UNIVERSITY MEDICAL CAMPUS — BOSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: BOSMANN, MARKUS — BOSTON UNIVERSITY MEDICAL CAMPUS
- Study coordinator: BOSMANN, MARKUS
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Acute Respiratory Distress Syndrome, Adult Respiratory Distress Syndrome